-
1 Comment
GenMark Diagnostics, Inc is currently in a long term uptrend where the price is trading 41.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.4.
GenMark Diagnostics, Inc's total revenue rose by 84.1% to $50M since the same quarter in the previous year.
Its net income has increased by 63.8% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 1.8% to $-10M since the same quarter in the previous year.
Based on the above factors, GenMark Diagnostics, Inc gets an overall score of 4/5.
| CurrencyCode | USD |
|---|---|
| Sector | Healthcare |
| Industry | Medical Devices |
| Exchange | NASDAQ |
| ISIN | US3723091043 |
| PE Ratio | None |
|---|---|
| Target Price | 22.52 |
| Market Cap | 2B |
| Dividend Yield | 0.0% |
| Beta | 3.07 |
As of April 21, 2021, GenMark Diagnostics, Inc. operates as a subsidiary of Roche Holding AG.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for GNMK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
